XORTX Therapeutics Inc.
XRTXNasdaq
$2.01
↓ -4.7%Jul 17 close · end-of-day
Price
1Y↓ -53.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
XORTX Therapeutics Inc. develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.
- CEO
- Allen W. Davidoff
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- British Columbia
- Website
- xortx.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 15, 2026
Jun 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.